Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models

[1]  A. Magi,et al.  The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma , 2019, Scientific Reports.

[2]  J. Ricci,et al.  Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies , 2018, Front. Oncol..

[3]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[5]  A. Aboussekhra,et al.  Let-7b inhibits cancer-promoting effects of breast cancer-associated fibroblasts through IL-8 repression , 2018, Oncotarget.

[6]  A. Beheshti,et al.  Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL , 2018, Nature Communications.

[7]  V. Bours,et al.  Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients , 2018, BMC Cancer.

[8]  A. Beheshti,et al.  Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma , 2017, Front. Immunol..

[9]  C. Lawrie,et al.  miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. , 2017, Cancer letters.

[10]  Hong Zhang,et al.  A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma , 2017, PloS one.

[11]  V. Taly,et al.  Droplet-Based Digital PCR: Application in Cancer Research. , 2017, Advances in clinical chemistry.

[12]  Jérôme Alexandre Denis,et al.  Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery , 2016, Molecular oncology.

[13]  M. Bøgsted,et al.  miR-155 as a Biomarker in B-Cell Malignancies , 2016, BioMed research international.

[14]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[15]  Y. Gui,et al.  Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. , 2016, Oncology letters.

[16]  A. Ribeiro-dos-Santos,et al.  MicroRNAs as Biomarkers of the Response to Treatment with ABVD Scheme in Hodgkin Lymphoma , 2015 .

[17]  R. Fu,et al.  miR-21 expression predicts prognosis in diffuse large B-cell lymphoma. , 2015, International journal of clinical and experimental pathology.

[18]  B. Dey,et al.  Agranulocytosis as a Part of Secondary Graft Failure after Allogenic Stem Cell Transplantation , 2015 .

[19]  M. Bøgsted,et al.  MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic review. , 2015, Danish medical journal.

[20]  M. J. You,et al.  Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. , 2015, Blood.

[21]  Yongjun Zhao,et al.  Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients , 2015, Genome Biology.

[22]  D. Neuberg,et al.  The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks , 2015, Cancer informatics.

[23]  S. Monti,et al.  Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. , 2015, The Journal of molecular diagnostics : JMD.

[24]  S. Ševčíková,et al.  Circulating microRNA as Biomarkers in Hematological Malignancies. , 2015, Experientia supplementum.

[25]  Kenneth W Witwer,et al.  Circulating microRNA biomarker studies: pitfalls and potential solutions. , 2015, Clinical chemistry.

[26]  M. Mraz,et al.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex , 2014, Leukemia.

[27]  Yue-Qin Chen,et al.  Circulating miRNAs in cancer: from detection to therapy , 2014, Journal of Hematology & Oncology.

[28]  B. Seliger,et al.  The role of microRNAs in the control of innate immune response in cancer. , 2014, Journal of the National Cancer Institute.

[29]  K. Pantel,et al.  Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases , 2014, British Journal of Cancer.

[30]  G. Calin,et al.  Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.

[31]  Atul Bhatnagar,et al.  Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2013, Clinical Cancer Research.

[32]  Sonali M. Smith,et al.  A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T‐cell lymphomas , 2013, British journal of haematology.

[33]  D. Turner,et al.  Epidemiology of non-Hodgkin lymphoma. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[34]  Deniz M. Ozata,et al.  Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma , 2013, Blood Cancer Journal.

[35]  Charusheila Ramkumar,et al.  Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1 , 2013, Nature Communications.

[36]  F. Jardin,et al.  MicroRNAs in lymphoma, from diagnosis to targeted therapy , 2013, Current opinion in oncology.

[37]  Stefano A Pileri,et al.  Diffuse large B-cell lymphoma. , 2013, Critical reviews in oncology/hematology.

[38]  Martin Reczko,et al.  DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows , 2013, Nucleic Acids Res..

[39]  T. Makino,et al.  The Downregulation of microRNA let-7a Contributes to the Excessive Expression of Type I Collagen in Systemic and Localized Scleroderma , 2013, The Journal of Immunology.

[40]  Bernhard Mlecnik,et al.  CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data , 2013, Bioinform..

[41]  Rang Xu,et al.  MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen , 2013, International Journal of Hematology.

[42]  Xin Wang,et al.  High expression and nuclear localization of β-catenin in diffuse large B-cell lymphoma. , 2012, Molecular medicine reports.

[43]  Ning Liu,et al.  Regulation of let-7 and its target oncogenes (Review). , 2012, Oncology letters.

[44]  Ivo Grosse,et al.  Functional microRNA targets in protein coding sequences , 2012, Bioinform..

[45]  Jian-yong Li,et al.  Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma , 2012, Annals of Hematology.

[46]  M. Jauberteau,et al.  Endogenous Neurotrophins and Trk Signaling in Diffuse Large B Cell Lymphoma Cell Lines Are Involved in Sensitivity to Rituximab-Induced Apoptosis , 2011, PloS one.

[47]  D. Oscier,et al.  Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. , 2011, Blood.

[48]  F. Slack,et al.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.

[49]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[50]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[51]  Zachary Shriver,et al.  Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.

[52]  Società Italiana di Emaferesi.  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , 2001 .